Class summary at a glance.

Every drug in the Histone Deacetylase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $13.1Mcombined across class
Total Rx claims: 739169 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Givinostat

Brand: DUVYZAT · 119 Part D claims (CY24) · 25 beneficiaries · First FDA approval: 2024-03-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $7.4M

Class share

56%

of class CY24 spend

View profile →

Vorinostat

Brand: ZOLINZA · 620 Part D claims (CY24) · 144 beneficiaries · First FDA approval: 2006-10-06

Brand-only (no generics) 268 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.7M

Class share

44%

of class CY24 spend

View profile →

Belinostat

Brand: Beleodaq · — Part D claims (CY24) · First FDA approval: 2014-07-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.